The high stakes for Huntington’s patients
Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington’s disease, and the outcome could be potentially devastating for patients.
That’s what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator’s changing perspective on UniQure’s trial affects patients, and patients’ attempts to petition the agency to reverse course.
Allison DeAngelis, Adam Feuerstein, and Elaine Chen
Go to statnews